Revance Therapeutics (RVNC)
(Delayed Data from NSDQ)
$5.81 USD
-0.04 (-0.68%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.83 +0.02 (0.34%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth NA Momentum NA VGM
Price, Consensus and EPS Surprise
RVNC 5.81 -0.04(-0.68%)
Will RVNC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RVNC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RVNC
How Much Upside is Left in Revance Therapeutics (RVNC)? Wall Street Analysts Think 55.02%
Can Revance Therapeutics (RVNC) Climb 98.64% to Reach the Level Wall Street Analysts Expect?
RVNC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Misses Revenue Estimates
Revance Therapeutics (RVNC) Loses -18.85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Lags Revenue Estimates
Other News for RVNC
Deals this week: Smartsheet, AT&T, BP, Cleveland-Cliffs, Vistra and more
Crown Labs tender offer for Revance delayed, expect deal to be completed - analyst
Revance Therapeutics falls as Crown Labs didn't start tender offer by deadline (update)
Beryl Capital Management LLC Acquires New Stake in Revance Therapeutics Inc
Revance Therapeutics falls as Crown Labs didn't start tender offer by deadline